Treating Bleeding and Improving Life Quality in Hereditary Hemorrhagic Telangiectasia
Official title: Antiangiogenic Therapy to Reduce Bleeding and Improve Health-Related Quality of Life in Hereditary Hemorrhagic Telangiectasia
Funded at Massachusetts General Hospital · NIH-11109583 · Data updated 2026-11-12
This project explores if a medication called bevacizumab can help adults with Hereditary Hemorrhagic Telangiectasia (HHT) by reducing bleeding and improving their daily lives.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | June 15, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $199,800 |
| NIH project number | 5K23HL159313-04 |
| Project ID | NIH-11109583 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults aged 21 and older who have Hereditary Hemorrhagic Telangiectasia (HHT) and are dependent on iron infusions or blood transfusions due to chronic bleeding.
✕Less likely to help
Patients who do not experience significant bleeding or are not dependent on transfusions or iron infusions may not directly benefit from this specific treatment approach.
What this research studies
Hereditary Hemorrhagic Telangiectasia (HHT) is a lifelong bleeding disorder with no approved treatments, causing fragile blood vessels that lead to severe nosebleeds and gut bleeding. This often results in anemia and a lower quality of life. Researchers have seen promising results using a medication called bevacizumab, which targets a growth factor that contributes to these fragile vessels. This project will conduct a clinical trial to confirm if bevacizumab can effectively reduce bleeding, decrease the need for transfusions, and improve how patients feel day-to-day.
Why it matters
Potential benefit: If successful, this medication could significantly reduce bleeding episodes, lessen the need for blood transfusions and iron infusions, and greatly improve the daily lives of people with HHT.
How similar studies have gone: Previous observational work has shown that bevacizumab can reduce transfusions and improve hemoglobin levels in HHT patients, but this trial aims to provide more definitive evidence.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Al-Samkari, Hanny T — Massachusetts General Hospital
- Study coordinator: Al-Samkari, Hanny T
Related research
Other NIH-funded projects on the same topics.
-
Direct measurement of RhD sensitization after early-pregnancy bleeding
This study tests how often Rh immunoglobulin given after bleeding in early pregnancy prevents RhD sensitization in pregnant people.
-
EpiMAX: a new injectable gel that stops GI bleeding quickly and for days
A new injectable hydrogel with epinephrine-loaded microparticles is designed to plug GI bleeds and provide immediate and lasting hemostasis for about 72 hours.
-
Dynamic risk tools to prevent blood clots and bleeding in cancer patients
A new AI-based approach will predict who among people with cancer starting treatment is at higher risk for blood clots or dangerous bleeding, helping doctors tailor preventive care.
-
Bleeding and Platelet Problems in Ehlers-Danlos Syndrome
This NIH grant looks at why people with Ehlers-Danlos syndrome bleed more and how platelet function is involved, with goals that could lead to better care during surgery or emergencies.
-
Long-acting RNA therapy to control fibrinolysis and reduce bleeding
A new RNA treatment delivered in lipids aims to slow down fibrinolysis and lessen bleeding for people with bleeding disorders or severe hemorrhage.
-
Thrombosis and Bleeding Risk in Medical Inpatients
A patient-facing program to better predict who is at risk for blood clots or bleeding during and after hospital stays, and to tailor prevention accordingly.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.